Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement

Protara Therapeutics, Inc.

2024-Q1 EPS reported -$0.97

Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.
Cash, equivalents and marketable securities $55.2M at Mar 31, 2024; combined with $42M net from April PIPE funds operations into 2026.
TARA-002 in NMIBC: 3-month CR rate 38% overall; 63% in CIS-only; no Grade 3+ related AEs.
ADVANCED-2 interim data (BCG-unresponsive/naïve) expected 2H 2024; registrational path aligned with FDA guidance.
FDA aligned on registrational path for IV Choline Chloride as choline source for PN-dependent patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Protara Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Protara Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-038756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.